Palbociclib has no clinically relevant effect on the QTc interval in patients with advanced breast cancer. [PDF]
, 2018 The aim of this study was to assess the potential effects of palbociclib in combination with letrozole on QTc. PALOMA-2, a phase 3, randomized, double-blind, placebo-controlled trial, compared palbociclib plus letrozole with placebo plus letrozole in ...
Durairaj, Chandrasekar +12 more
core +2 more sources
eIF4A inhibitors suppress cell-cycle feedback response and acquired resistance to CDK4/6 inhibition in cancer [PDF]
, 2019 CDK4/6 inhibitors are FDA-approved drugs for estrogen receptor-positive (ER+) breast cancer and are being evaluated to treat other tumor types, including KRAS-mutant non-small cell lung cancer (NSCLC).
Cencic, Regina +13 more
core +1 more source
Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. [PDF]
, 2017 Background: CDK 4 and 6 inhibitors (CDK4/6i), which arrest unregulated cancer cell proliferation, show clinical efficacy in breast cancer. Unexpectedly, a patient treated on a CDK4/6i-based trial, as first-line therapy in metastatic breast cancer ...
Abouharb, Sausan +12 more
core +2 more sources
Pharmaceutics, 2022 Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet +15 more
doaj +1 more source
Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic [PDF]
, 2020 The epidemiological emergency caused by CoV-2 (COVID-19) has changed priorities in breast cancer management. In those places where the pandemic has had the greatest effect, it is of paramount importance for most patients to be at home, reducing or ...
Martí, Covadonga +1 more
core +1 more source
Technology in Cancer Research & Treatment, 2022 Background: Palbociclib is the most widely used cyclin-dependent kinase 4/6 inhibitor in China, but its early application efficacy on Chinese metastatic breast cancer (MBC) patients was reported deficiently.
Yusi Zhang MS +4 more
doaj +1 more source
Not So Fast: Cultivating miRs as Kinks in the Chain of the Cell Cycle. [PDF]
, 2017 In this issue of Cancer Cell, Hydbring and colleagues define a novel class of microRNAs (miRNAs), deemed cell-cycle-targeting miRNAs, that target several cyclins/CDKs, reduce tumor cell growth, and induce apoptosis.
Knudsen, Karen E., Schiewer, Matthew J.
core +2 more sources
Comparison of TCGA and GENIE genomic datasets for the detection of clinically actionable alterations in breast cancer. [PDF]
, 2019 Whole exome sequencing (WES), targeted gene panel sequencing and single nucleotide polymorphism (SNP) arrays are increasingly used for the identification of actionable alterations that are critical to cancer care.
Carpten, John D +4 more
core +3 more sources
Breast, 2021 Background: This study aimed to provide insights into the real-world use of palbociclib, dose reductions, and drug effectiveness in (older) patients with advanced breast cancer (BC).
R.K. Ismail +10 more
doaj +1 more source
P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib.
PLoS ONE, 2019 The P16 (CDKN2Aink4a) gene is an endogenous CDK4/6 inhibitor. Palbociclib (PD0332991) is an anti-CDK4/6 chemical for cancer treatment. P16 is most frequently inactivated by copy number deletion and DNA methylation in cancers. It is well known that cancer
Paiyun Li +4 more
doaj +1 more source